PMID- 27013890
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160325
LR  - 20201001
IS  - 1178-6930 (Print)
IS  - 1178-6930 (Electronic)
IS  - 1178-6930 (Linking)
VI  - 9
DP  - 2016
TI  - Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast 
      cancer.
PG  - 959-76
LID - 10.2147/OTT.S100499 [doi]
AB  - PURPOSE: The aim of this study was to evaluate the therapeutic efficacy and 
      safety of trastuzumab emtansine (T-DM1) for the treatment of patients with human 
      epidermal growth factor receptor 2-positive breast cancer. METHODS: We performed 
      a systemic review and meta-analysis of the relevant published clinical studies. A 
      computerized search was performed for controlled clinical trials of T-DM1 in 
      targeted treatment. Overall survival, progression-free survival, objective 
      response rate, symptom progression free, and adverse events (AEs) were evaluated. 
      RESULTS: Eight eligible trials with a total of 2,016 patients with breast cancer 
      were included in the present meta-analysis. The treatment of patients with breast 
      cancer with T-DM1 was associated with significantly increased overall and 
      progression-free survival when compared with controls (P<0.0001). An analysis of 
      the objective response rate and symptom progression free also demonstrated 
      favorable results for T-DM1 treatment (P</=0.0001). There was no significant 
      difference between the T-DM1 and control groups with respect to nonhematologic or 
      hematologic AEs (P=0.99 and P=0.30, respectively). CONCLUSION: Overall, T-DM1 is 
      efficacious in the treatment of patients with human epidermal growth factor 
      receptor 2-positive breast cancer and low rates of AEs compared with controls.
FAU - Ma, Bo
AU  - Ma B
AD  - Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, 
      People's Republic of China.
FAU - Ma, Qianqian
AU  - Ma Q
AD  - University Hospital of Tuebingen, Tuebingen, Germany.
FAU - Wang, Hongqiang
AU  - Wang H
AD  - Department of Oncology, Hospital of Zhoushan, Zhoushan, Zhejiang, People's 
      Republic of China.
FAU - Zhang, Guolei
AU  - Zhang G
AD  - Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, 
      People's Republic of China.
FAU - Zhang, Huiying
AU  - Zhang H
AD  - Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, 
      People's Republic of China.
FAU - Wang, Xiaohong
AU  - Wang X
AD  - Affiliated Central Hospital of Huzhou Teachers College, Huzhou, Zhejiang, 
      People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20160229
PL  - New Zealand
TA  - Onco Targets Ther
JT  - OncoTargets and therapy
JID - 101514322
PMC - PMC4778787
OTO - NOTNLM
OT  - HER2
OT  - T-DM1
OT  - breast cancer
OT  - efficacy
OT  - meta-analysis
EDAT- 2016/03/26 06:00
MHDA- 2016/03/26 06:01
PMCR- 2016/02/29
CRDT- 2016/03/26 06:00
PHST- 2016/03/26 06:00 [entrez]
PHST- 2016/03/26 06:00 [pubmed]
PHST- 2016/03/26 06:01 [medline]
PHST- 2016/02/29 00:00 [pmc-release]
AID - ott-9-959 [pii]
AID - 10.2147/OTT.S100499 [doi]
PST - epublish
SO  - Onco Targets Ther. 2016 Feb 29;9:959-76. doi: 10.2147/OTT.S100499. eCollection 
      2016.